| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | ||||||||||
License and milestone fees | ||||||||||
- | - | - | - | - | 57,815 | 39,455 | 24,227 | 9,161 | 6,393 | 5,698 |
Royalty revenue | ||||||||||
- | - | - | - | - | 13,867 | 10,346 | 592 | - | - | - |
Non-cash royalty revenue related to the sale of future royalties | ||||||||||
- | - | - | - | - | 5,484 | - | - | - | - | - |
Research and development support | ||||||||||
- | - | - | - | - | 2,848 | 7,187 | 7,873 | 4,517 | 7,256 | 5,365 |
Clinical materials revenue | ||||||||||
- | - | - | - | - | 5,527 | 2,908 | 2,843 | 2,679 | 5,656 | 2,880 |
Total revenues | ||||||||||
82,271 | 53,446 | 115,447 | 48,628 | 60,002 | 85,541 | 59,896 | 35,535 | 16,357 | 19,305 | 13,943 |
Operating expenses: | ||||||||||
Research and development | ||||||||||
114,522 | 174,456 | 139,739 | 141,312 | 148,077 | 111,768 | 106,958 | 87,073 | 69,192 | 63,453 | 50,280 |
General and administrative | ||||||||||
38,489 | 36,746 | 33,911 | 38,528 | 36,916 | 28,228 | 24,469 | 21,471 | 20,422 | 16,040 | 14,898 |
Restructuring charge | ||||||||||
21,433 | 3,693 | 779 | 4,431 | - | - | - | - | - | - | - |
Total operating expenses | ||||||||||
174,444 | 214,895 | 174,429 | 184,271 | 184,993 | 139,996 | 131,427 | 108,544 | 89,614 | 79,493 | 65,178 |
Loss from operations | ||||||||||
-92,173 | -161,449 | -58,982 | -135,643 | -124,991 | -54,455 | -71,531 | -73,009 | -73,257 | -60,188 | -51,235 |
Investment income, net | ||||||||||
4,424 | 4,227 | 1,146 | 473 | 325 | 69 | 44 | 126 | 66 | 218 | 176 |
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes | ||||||||||
16,879 | 10,631 | 13,682 | 18,593 | 20,130 | 5,437 | - | - | - | - | - |
Interest expense on convertible senior notes | ||||||||||
95 | 95 | 3,040 | 2,387 | 138 | - | - | - | - | - | - |
Non-cash debt conversion expense | ||||||||||
- | - | 22,915 | - | - | - | - | - | - | - | - |
Other expense, net | ||||||||||
590 | -895 | 1,461 | -583 | 117 | -916 | 123 | 72 | -128 | 1,696 | -118 |
Net loss | ||||||||||
-104,133 | -168,843 | -96,012 | -156,733 | -144,817 | -60,739 | -71,364 | -72,811 | -73,319 | -58,274 | -50,912 |
Loss before benefit for income taxes | ||||||||||
- | - | - | - | - | - | - | - | - | - | -51,177 |
Benefit for income taxes | ||||||||||
- | - | - | - | - | - | - | - | - | - | -265 |
Basic and diluted net loss per common share (in dollar per share) | ||||||||||
-0.70 | -1.21 | -0.98 | -1.80 | -1.67 | -0.71 | -0.83 | -0.87 | -0.95 | -0.85 | -0.87 |
Basic and diluted weighted average common shares outstanding (in shares) | ||||||||||
148,311 | 139,946 | 98,068 | - | 86,976 | 86,038 | 85,481 | 84,063 | 76,814 | 68,919 | 58,845 |
Other Comprehensive Loss | ||||||||||
- | - | - | - | - | - | - | - | - | -282 | - |
Total comprehensive loss | ||||||||||
-104,133 | -168,843 | -96,012 | - | -144,817 | -60,739 | -71,364 | -72,811 | -73,319 | -58,556 | - |
License and milestone fees | ||||||||||
Total revenues | ||||||||||
34,788 | 15,280 | 79,469 | 15,305 | 26,915 | - | - | - | - | - | - |
Royalty revenue | ||||||||||
Total revenues | ||||||||||
- | - | - | - | 195 | - | - | - | - | - | - |
Non-cash royalty revenue related to the sale of future royalties | ||||||||||
Total revenues | ||||||||||
47,415 | 32,154 | 28,142 | 26,218 | 25,299 | - | - | - | - | - | - |
Research and development support | ||||||||||
Total revenues | ||||||||||
68 | 1,377 | 3,482 | 5,175 | 4,014 | - | - | - | - | - | - |
Clinical materials revenue | ||||||||||
Total revenues | ||||||||||
- | 4,635 | 4,354 | 1,930 | 3,579 | - | - | - | - | - | - |